Fig. 5: The intrinsic capacity of T-cells from peripheral blood of B-NHL patients to induce cytotoxicity is comparable to that of healthy donor T-cells. | Blood Cancer Journal

Fig. 5: The intrinsic capacity of T-cells from peripheral blood of B-NHL patients to induce cytotoxicity is comparable to that of healthy donor T-cells.

From: Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Fig. 5

A Dose-response of and B maximal cytotoxicity induced by epcoritamab in B-NHL cells in the presence of allogeneic healthy donor PBMCs or autologous B-NHL patient PBMCs in a 10:1 E:T ratio (n = 5; Wilcoxon matched-pairs signed rank test; ns).

Back to article page